Infectious Disease Testing Market - Industry Analysis, Market Size, Share, Trends, Application Analysis, Growth And Forecast 2022-2027

Infectious Disease Testing Market size is estimated to reach $42.4 billion by 2027, growing at a CAGR of 6.6% during the forecast period 2022-2027. Infectious diseases can be demarcated as medical disorders which are erupted by bacteria and viruses. Therefore, several laboratory procedures are taken into account to diagnose and identify infections through the collected respiratory sample. The presence of present-time technologies like DNA sequencing & Next-generation sequencing has made disease management somewhat easy. These techniques are paramount applications in comprehending the relationship between viruses and bacteria. Also, they are proficient in recording genetic mutations that make antibiotics futile. Furthermore, methods like isothermal nucleic acid amplification technology are replacing polymerase chain reaction (PCR) technology in magnification of DNA sequencing. The infectious disease testing market outlook is exceptionally astonishing considering the unremitting pace at which infectious ailments are prevailing across the globe. The unrivaled speed of infectious maladies’ pervasiveness is a preeminent factor driving the infectious disease testing market. Infections like Influenza, genital herpes, hepatitis, and others are augmenting steadily day after day. In addition to that, broadening research activities and shooting up demand for POC testing are factors set to drive the growth of the Infectious Disease Testing Market for the period 2022-2027.

The report: “Infectious Disease Testing Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Infectious Disease Testing Market.

 

• Geographically, the North America Infectious Disease Testing Market accounted for the highest revenue share in 2021. Nevertheless, Asia-pacific is poised to dominate the market over the period 2022-2027.
• Augmenting health cognizance and enlarging research facilities with proliferating investments by governments and private players is said to be a preeminent driver driving the growth of the Infectious Disease Testing Market. the exorbitant cost of tools required to perform extensive research and the deficiency of capable specialists is said to reduce the market growth.
• Detailed analysis on the Strength, Weaknesses, and Opportunities of the prominent players operating in the market will be provided in the Infectious Disease Testing Market report.
•  Infectious Disease Testing Market Segment Analysis-By Sickness Type
• The Infectious Disease Testing Market based on the sickness type can be further segmented into cardiovascular infections, bacterial infections (TB, syphilis, strep throat, bacterial vaginosis, gonorrhea, and others), viral infections (influenza, Ebola, zika, hepatitis, SARS-CoV-2), sexually transmitted infections (genital herpes, human papillomavirus, HIV, and others), gastro-Intestinal Infections, and others. The viral infection segment held the largest share in 2021. The growth is owing to a sweeping preponderance in the number of people inflicted with infectious sicknesses. Oftentimes, the protein spikes of disease mutate and find a way to evade the effects of antibiotics. Take SARS-CoV-2, for instance, this virus has mutated a number of times which is the principal cause behind the surge of this infectious disease. On another hand, hepatitis is also prevailing at the best of its capacity as alcohol consumptions are sky-rocketing. The infectious and cardiovascular infections segment is estimated to be the fastest-growing with a CAGR of 8.3% over the forecast period 2022-2027. Dull immunity is an easy target of such contagions. Therefore, prolonged sittings during office hours, poor diet intake, and worsening situation of environmental pollution are augmenting the prevalence of cardiovascular complications and other infections and emerging as a prominent reason behind the growth in respective segments.

The Infectious Disease Testing Market based on end-user can be further segmented into hospitals, clinics, research laboratories, and academic institutes. The hospital segment held the largest share in 2021. The growth is owing to the comprehensive existence of hospitals in urban areas and the countryside. Moreover, the hospitals are comparatively well-furnished than other medical facilities therefore can better extend diagnostic and treatment conveniences at the same spot which makes people more willing to use hospitals as it saves their time. The academic and research institutes have an enormous role to play in infectious disease testing markets as they conduct all obligatory research and engender breakthroughs but their function is circumscribed to research only. They don’t offer treatment to the patients as hospitals do. Therefore, the hospital segment is estimated to be the fastest-growing segment with a CAGR of 7.7% over the forecast period 2022-2027. This growth is owing to heavy investment from governments to better handle the ongoing crisis that is “COVID-19.” As a result, the infrastructure of poorly equipped hospitals situated in impoverished areas is ameliorating. Moreover, hospitals are overwhelmed with catapulting corona cases which are the leading cause of progress in this segment.

The Infectious Disease Testing Market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and the Rest of the World. North America held the largest share with 36% of the overall market in 2021. The growth in this segment is owing to the factors such as accruing COVID-19 infections cases in the U.S. In the name of freedom, people aren’t wearing masks, not taking vaccines, and not following government orders on social distancing. Moreover, most vaccines circulating worldwide are American which means extensive research is being conducted by research laboratories. Genital herpes is very common in the US. According to a report, 1 out of 5 adults experiences this condition every year. However, Asia-pacific is expected to be the fastest-growing segment over the forecast period 2022-2027. This growth is owing to overcrowded cities that act as a conducive environment for transmissions of infections. Poor sanitary habits are still prevailing among people residing in deprived areas. Therefore, incidences of diarrhea, hepatitis, and dengue are enlarging. For instance, India witnessed over 164,100 cases of dengue in 2021. Besides, with growing soft power of countries like India and China gives good ground for vaccines produced by these nations to attain acceptance by WHO and other countries which is encouraging these states to magnify their research activities.

The spread of infections has become a new normal for contemporary society that it doesn’t even scare people now as if they are used to it. The world is not just reeling under the weight of COVID-19 infections but it seems that many other infections are just waiting for their turn to explode around the globe. Hepatitis cases are surging worldwide. For instance, every year the U.S. records around 3,000 cases of this inflammation. In 2020, there were more than 350 million cases of hepatitis B and C. Moreover, the intensification of sexually transmitted infections has come to the foreground in recent years like never before. More than 35 million cases of HIV were recorded in 2020.

 

Convenient testing options and technological breakthroughs in research are Expected to Boost Product Demand.

The swift modernization has a fair share in molding people's behaviors worldwide. With augmenting health awareness more and more people are undergoing diagnostic procedures to ensure a proper distance from infections. Moreover, the existence of expedient options like the point of care (POC) testing. The POC extends several benefits to patients like it eliminates the need to wait for several days after specimen collection. Moreover, considering the ongoing scenario governments have augmented the overall healthcare and research spending. For instance, in 2020 China amplified its R&D spending by 2.4% of its GDP. Moreover, India soared its healthcare spending by 137% for FY22.

Many people are not willing to undergo diagnostic procedures which can hamper the growth of the aforementioned market. According to the Centers for Disease Control and Prevention, except for COVID-19, the total number of notifiable infectious diseases cases in 2020 was 6,366,176, a decrease of 41.38% year-on-year compared with 2019. There are many people who are working round the clock to build a narrative that vaccine is harmful or they can leave vaccinated person with incurable conditions. Moreover, the countless number of riches is a prerequisite to setting up manufacturing plants and research facilities which can be a big setback in the growth of the infectious disease testing market as many businesses are dooming due to widescale lockdowns.

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Infectious Disease Testing Market. Key companies of this market are-

 

1. Qiagen Company
2. Cardinal Health
3. Siemens AG
4. Johnson & Johnson
5. Quest Diagnostics
6. Thermo Fisher Scientific
7. Sofina Holding Company
8. Quidel Corporation
9. Danaher Corporation
10. Ingersoll-Rand Plc

• On December 23, 2021, California, United States-based diagnostic healthcare products manufacturing company “Quidel Corporation” announced that it has reached an acquisition agreement with US-based in vitro diagnostic corporation “Ortho Clinical Diagnostics.” According to the transaction agreement, Quidel will pay an amount of $6 billion with $24.68 per share to wrap up the process.
• On June 1, 2021, Washington, D.C, United States-based conglomerate “Danaher Corporation” publicized the successful acquisition of Canada-based company “Precision NanoSystems.” The financials of the transaction were not disclosed. Moreover, as Precision is famous for genetic medicine solutions the acquisition is anticipated to strengthen the operations of Cytiva and Pall which are subsidiaries of Danaher.
• On March 12, 2021, US-based healthcare services company “Cardinal Health” announced that the company has signed an agreement with the company “Hellman & Friedman.” Based on this agreement Cardinal Health will sell its Cordis business for a total price of $1 billion. The process is anticipated to be concluded by the initial half of 2022.
•